From lab to market: The PacifiCan and ARTMS partnership

Two ARTMS lab technicians look at the Quantm Irradiation target station at the ARTMS lab.]

Global medical isotope shortages? Thankfully, ARTMS has a solution.

Medical isotopes are used in cancer, cardiac and lung disease diagnosis. Burnaby-based ARTMS is producing groundbreaking technology allowing medical providers to generate their own essential isotopes.

ARTMS holds exclusive global commercialization rights to its award-winning, proprietary Quantum Irradiation System (QIS) hardware which enables hospitals and other medical facilities to use their pre-existing equipment to produce Tc-99m along with other medical isotopes.

The ARTMS quantum irradiation system

 

The result? Less global shortage, which means more medical knowledge and more efficient diagnoses. This also helps physicians and researchers to produce radioisotopes locally and in a cost-effective manner.

$1.5M in PacifiCan funding has helped ARTMS:

Headshot of Paul Schaffer, PhD, Chief Technology Officer, ARTMS, quote reads: Pacifican has been a significant enabler of ARTMS, helping the company to hire and retain key talent and advance our technology into the market. ARTMS is now on-track to reach key milestones that will solidify the company’s long-term success.

 


On social media

Page details

Date modified: